Tenax Therapeutics (TENX) Other Gross PP&E Adjustments (2012 - 2022)
Tenax Therapeutics recorded quarterly Other Gross PP&E Adjustments of -$179503.0 in Q4 2022, up 13.43% quarter-over-quarter from -$207359.0 in Q3 2022, and up 37.61% year-over-year from -$130447.2 in Q4 2021.
Tenax Therapeutics' Other Gross PP&E Adjustments history runs 11 years deep, the most recent figure standing at -$179503.0 for Q4 2022.
- In Q4 2022, Other Gross PP&E Adjustments rose 37.61% year-over-year to -$179503.0; the TTM figure through Dec 2022 stood at -$179503.0 (up 37.61% YoY), while the FY2022 annual figure was -$179503.0, up 37.61% from the prior year.
- Other Gross PP&E Adjustments came in at -$179503.0 for Q4 2022 at Tenax Therapeutics, up from -$207359.0 in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $485053.0 in Q3 2018 to a low of -$295665.0 in Q2 2021.
- A 5-year average of -$43681.7 and a median of -$104553.0 in 2019 frame the typical range for Other Gross PP&E Adjustments.
- Across the five-year window, Other Gross PP&E Adjustments surged 105.96% in 2018 and slumped 3195.54% in 2022, its largest moves.
- Tenax Therapeutics' Other Gross PP&E Adjustments stood at $451454.0 in 2018, then tumbled by 119.67% to -$88779.0 in 2019, then surged by 60.05% to -$35471.0 in 2020, then tumbled by 711.06% to -$287692.0 in 2021, then soared by 37.61% to -$179503.0 in 2022.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered -$179503.0, -$207359.0, and -$234662.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -179,503.00 |
| Dec 31, 2022 | -179,503.00 |
| Sep 30, 2022 | -207,359.00 |
| Sep 30, 2022 | -207,359.00 |
| Jun 30, 2022 | -234,662.00 |
| Jun 30, 2022 | -234,662.00 |
| Mar 31, 2022 | -261,435.00 |
| Mar 31, 2022 | -261,435.00 |
| Dec 31, 2021 | -287,692.00 |
| Dec 31, 2021 | -287,692.00 |
| Sep 30, 2021 | -270,410.00 |
| Sep 30, 2021 | -270,410.00 |
| Jun 30, 2021 | -295,665.00 |
| Jun 30, 2021 | -295,665.00 |
| Mar 31, 2021 | -7,933.00 |
| Mar 31, 2021 | -7,933.00 |
| Dec 31, 2020 | -35,471.00 |
| Dec 31, 2020 | -35,471.00 |
| Sep 30, 2020 | -67,469.00 |
| Sep 30, 2020 | -67,469.00 |
| Jun 30, 2020 | -72,191.00 |
| Jun 30, 2020 | -72,191.00 |
| Mar 31, 2020 | -120,327.00 |
| Mar 31, 2020 | -120,327.00 |
| Dec 31, 2019 | -88,779.00 |
| Dec 31, 2019 | -88,779.00 |
| Sep 30, 2019 | -65,576.00 |
| Sep 30, 2019 | -65,576.00 |
| Jun 30, 2019 | -140,909.00 |
| Jun 30, 2019 | -140,909.00 |
| Mar 31, 2019 | -146,720.00 |
| Mar 31, 2019 | -146,720.00 |
| Dec 31, 2018 | 451,454.00 |
| Dec 31, 2018 | 451,454.00 |
| Sep 30, 2018 | 485,053.00 |
| Sep 30, 2018 | 485,053.00 |
| Jun 30, 2018 | 224,996.00 |
| Jun 30, 2018 | 224,996.00 |
| Mar 31, 2018 | 446,964.00 |
| Mar 31, 2018 | 446,964.00 |
| Dec 31, 2017 | 219,190.00 |
| Dec 31, 2017 | 219,190.00 |
| Sep 30, 2017 | 455,876.00 |
| Sep 30, 2017 | 455,876.00 |
| Jun 30, 2017 | 459,810.00 |
| Jun 30, 2017 | 459,810.00 |
| Mar 31, 2017 | 235,141.00 |
| Mar 31, 2017 | 235,141.00 |
| Dec 31, 2016 | 231,869.00 |
| Dec 31, 2016 | 231,869.00 |
| Sep 30, 2016 | 485,053.00 |
| Sep 30, 2016 | 485,053.00 |
| Jun 30, 2016 | 644,406.00 |
| Jun 30, 2016 | 644,406.00 |
| Mar 31, 2016 | 273,060.00 |
| Mar 31, 2016 | 273,060.00 |
| Dec 31, 2015 | 270,176.00 |
| Dec 31, 2015 | 270,176.00 |
| Apr 30, 2015 | 253,487.00 |
| Apr 30, 2015 | 253,487.00 |
| Jan 31, 2015 | 813,276.00 |
| Jan 31, 2015 | 813,276.00 |
| Oct 31, 2014 | 813,824.00 |
| Oct 31, 2014 | 813,824.00 |
| Jul 31, 2014 | 826,012.00 |
| Jul 31, 2014 | 826,012.00 |
| Apr 30, 2014 | 813,824.00 |
| Apr 30, 2014 | 813,824.00 |
| Jan 31, 2014 | 898,444.00 |
| Jan 31, 2014 | 898,444.00 |
| Oct 31, 2013 | 902,563.00 |
| Oct 31, 2013 | 902,563.00 |
| Jul 31, 2013 | 264,503.00 |
| Jul 31, 2013 | 264,503.00 |
| Apr 30, 2013 | 265,889.00 |
| Apr 30, 2013 | 265,889.00 |
| Jan 31, 2013 | 266,410.00 |
| Jan 31, 2013 | 266,410.00 |
| Oct 31, 2012 | 1.09 Mn |
| Oct 31, 2012 | 1.09 Mn |
| Jul 31, 2012 | 1.11 Mn |
| Jul 31, 2012 | 1.11 Mn |
| Apr 30, 2012 | 1.10 Mn |
| Apr 30, 2012 | 1.10 Mn |